| MEDI0457 / AstraZeneca |
NCT02501278: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 0 | Europe | INO-3112 vaccine, Radiotherapy (Extrernal beam radiotherapy + brachytherapy), Cisplatin chemotherapy | European Organisation for Research and Treatment of Cancer - EORTC, Inovio Pharmaceuticals, Centre Hospitalier Universitaire Vaudois | Uterine Cervical Neoplasms | 05/19 | 05/21 | | |
NCT04001413: Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients |
|
|
| Withdrawn | 2 | 0 | US | MEDI0457, INO-3112, Durvalumab, MEDI4736 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma | 03/21 | 03/21 | | |
NCT03162224: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer |
|
|
| Completed | 1b/2a | 35 | US | MEDI0457, INO-3112, CELLECTRA®5P device, CELLECTRA 2000, Durvalumab, MEDI4736 | MedImmune LLC | Head and Neck Cancer, Human Papilloma Virus | 03/21 | 03/21 | | |
|
|
NCT02163057: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma |
|
|
| Completed | 1/2 | 22 | US | INO-3112, VGX-3100, INO-9012, CELLECTRA™-5P | Inovio Pharmaceuticals, University of Pennsylvania | Head and Neck Squamous Cell Cancer | 01/17 | 01/17 | | |
NCT02172911: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer |
|
|
| Completed | 1/2 | 10 | US | INO-3112, VGX-3100, INO-9012, CELLECTRA™-5P | Inovio Pharmaceuticals | Cervical Cancer | 09/17 | 09/17 | | |
